Baird Downgrades Exactech (EXAC) to Neutral
Baird downgrades Exactech (Nasdaq: EXAC) from Outperform to Neutral. Price target lowered from $21 to $16.
Exactech, Inc. (Exactech) develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
